SecBot SecBot

LPCN

Lipocine Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001535955 Biotech & Drug Discovery
$1.44 −0.02 (−1.37%)
Oct 23 4:00 PM ET · prev $1.46
Market cap
$12.0M
Nano cap
Consensus
Buy
75% Buy or better · 8 analysts
Median target
$5.00
+247% · range $4.00–6.00
Next earnings
Nov 4
in 9 days · EPS est. −$0.35
1 year
−48.9%
from $2.82 · Oct 27
30 days
−31.1%
from $2.09
52-week range
$1.44–11.26
at the low
Avg volume 20D
5.66M
Oct 7 spike 105.84M
Short interest
🔒 Subscribers only
Insider net
+$516.8K
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read BULLISH 8 reports · 90 days
Balance 0 bearish · 2 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 6/8 ·Next Earnings date, Nov 4, 2026
Strongest BULLISH Lipocine announced that Health Canada approved TLANDO (testosterone undecanoate) capsules for testosterone…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $516.8K at an average $2.06. No open-market sales. Price is 30% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 6 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    6 of 8 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.430 → −$0.355 over 90 days.

  • TrendDOWNTREND

    30% below its 50-day average. New closing low $1.44 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCDOUBLED95,227$243.8K
CITADEL ADVISORS LLCDOUBLED81,221$207.9K
RENAISSANCE TECHNOLOGIES LLCADD69,209$177.2K
VANGUARD FIDUCIARY TRUST COADD54,539$139.6K
DIMENSIONAL FUND ADVISORS LPADD36,775$94.1K
OSAIC HOLDINGS, INC.ADD238$609.00
JANE STREET GROUP, LLCADD20,027$160.0K
DIMENSIONAL FUND ADVISORS LPADD19,122$152.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts
Buy 75% rate it Buy or better
Strong Buy2Buy4Hold2Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +247%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 21, 2026HC Wainwright & Co.
REITERATE
REITERATENeutral

Insider ledger

Form 4
$516.8K
bought · 2 insiders
$0
sold · 0 insiders
−30.2%
vs their $2.06 cost
DateInsiderTypeValue
Sep 30, 2026
Higuchi John W.
Director
BUY$35.6K
Sep 29, 2026
Higuchi John W.
Director
BUY$19.4K
Sep 28, 2026
Higuchi John W.
Director
BUY$27.1K
Aug 3, 2026
Grissinger Michael
Director
AWARD$4.2K
Jun 29, 2026
Patel Mahesh V.
Chief Executive Officer
AWARD$131.4K
Jun 3, 2026
Ono Richard Dana
Director
AWARD$3.9K
Jun 3, 2026
Jene Jill M.
Director
AWARD$3.9K
Jun 3, 2026
Higuchi John W.
Director
AWARD$3.9K

Earnings setup

Estimates
Nov 4
reports in 9 days
−$0.35
EPS estimate, this quarter
+17%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.35-$0.39–-$0.32-10.9%$159.5K
Next Q-$0.36-$0.40–-$0.33+8.8%$162.5K
Current FY-$1.54-$1.55–-$1.54+0.3%$631.3K
Next FY-$1.34-$1.65–-$1.03+18.8%$745.0K

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 SEC
Lipocine Inc. filed an 8-K on October 20, 2026, solely to disclose that it has updated its corporate presentation used…
8-K — Impact 2/10
Oct 7, 2026 SEC
Lipocine announced that Health Canada approved TLANDO (testosterone undecanoate) capsules for testosterone replacement…
8-K — Impact 5/10
Sep 30, 2026 Insider
Higuchi John W. bought 15,970 shares
Director @ $2.23 ($35.6K)
Sep 29, 2026 Insider
Higuchi John W. bought 9,037 shares
Director @ $2.15 ($19.4K)
Sep 28, 2026 Insider
Higuchi John W. bought 12,561 shares
Director @ $2.16 ($27.1K)
Sep 16, 2026 SEC
Lipocine Inc. filed an 8-K to report that it presented at the H.C. Wainwright 28th Annual Global Investor Conference…
8-K — Impact 2/10
Aug 4, 2026 Earnings
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutica
Jun 30, 2026 Inst.
JANE STREET GROUP, LLC — DOUBLED
95,227 shares ($243.8K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
LPCN Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Aug 4, 2026
Earnings
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel…
Aug 3, 2026
Press release
Lipocine Appoints Michael J. Grissinger to Board of Directors
SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology…
Aug 3, 2026
Earnings date
LPCN Q2 2026 Earnings Scheduled — 2026-08-03
May 6, 2026
Earnings date
LPCN Q1 2026 Earnings Scheduled — 2026-05-06
Apr 1, 2026
Trial readout
Results Pending: LPCN 1154A (Phase 3) — Completed 75d ago
Trial: A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD Sponsor: Lipocine Inc. Phase: Phase 3 | Completed…

SecBot reports

17 filings · 2 bullish · 3 bearish · 12 neutral
All LPCN filing & press-release reports (17)